Thirteen Years and beyond- continuous influence of Novartis AG v. Union of India (2013)
Although the Supreme Court in Novartis AG v. Union of India & Ors. acknowledged that, as a matter of patent theory, claims cannot extend beyond the enabling disclosure, the judgment has at times been selectively relied upon to contend that no meaningful distinction exists between mere coverage of subject matter by a broad genus claim and its disclosure through an enabling teaching
Introduction
Few judicial pronouncements in the annals of Indian intellectual property law have generated as much academic commentary, policy debate, and litigation consequence as the Supreme Court’s judgment in Novartis AG v. Union of India,1 delivered on April 1, 2013. More than a decade later, the decision endures not merely as a textbook citation but as a living doctrinal instrument shaping pharmaceutical patent examination, influencing the grant or refusal of interim injunctions, and reinforcing India’s foundational commitment to affordable medicines. To understand its continuing relevance, it is important to revisit what the Court held, why it held so, and how that holding continues to echo across courtrooms, patent offices, and corporate boardrooms thirteen years on.
Background and Journey Through the Courts
The dispute originated when Novartis AG filed Indian Patent Application No. 1602/MAS/1998, seeking a product patent for the β-crystalline form of Imatinib Mesylate—a breakthrough anticancer drug marketed globally as Gleevec/Glivec and used in the treatment of Chronic Myeloid Leukaemia (CML). The application claimed Swiss priority dated July 18, 1997 and was taken out of India’s “mailbox”2 mechanism after the Patents (Amendment) Act, 2005 came into force. The application was met with five pre-grant oppositions filed by Indian generic manufacturers and a patient-advocacy NGO, reflecting the enormous public-health stakes at play.
On January 25, 2006, the Assistant Controller of Patents rejected the application on grounds of anticipation, obviousness, a bar under Section 3(d), and a defect in the priority date. After the Intellectual Property Appellate Board (IPAB)3 was constituted, the matter was transferred to it. In its June 2009 decision, the IPAB reversed the findings on anticipation and obviousness but ultimately refused the product patent, holding that the claim fell foul of both Section 3(d) and Section 3(b). Process claims, however, were allowed. Novartis filed Special Leave Petitions before the Supreme Court, and objectors including Natco Pharma, Cipla, Ranbaxy, and the Cancer Patients Aid Association entered appearance. Recognizing the profound public-health significance of the matter, the Supreme Court decided to hear the appeals on their merits.
What the Supreme Court Actually Held
The Court’s reasoning proceeded on two levels. First, it drew a sharp and analytically important distinction between “invention” within the meaning of Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970, and “patentability” under Section 3. This bifurcation was not merely semantic—it established that satisfying the definition of an “invention” is a necessary but not sufficient condition for obtaining a patent; the claimed subject matter must also clear the separate patentability filters under Section 3.
Second, and critically, the Court undertook an extensive examination of the Zimmermann US Patent 5,521,1844, contemporaneous scientific literature (including Cancer Research 1996 and Nature Medicine 1996), and Novartis’s own FDA filings. On this basis, the Court held that Imatinib Mesylate was already disclosed, enabled, and known in the prior art. The β-crystalline form—being a polymorph of a known substance—was therefore required to satisfy the heightened test under Section 3(d) as amended in 2005.
The only advantages demonstrated for the β-form were improved flow, enhanced thermodynamic stability, reduced hygroscopicity, and approximately 30% higher bioavailability. The Court held that these were physical and manufacturing properties, not evidence of superior therapeutic efficacy. The specification itself admitted that the pharmacological effects of the β-form were identical to those of the known Imatinib free base. With no credible experimental or clinical data showing a significant improvement in therapeutic outcome, the Court held that the bar of Section 3(d) was not crossed. The appeals were dismissed; the cross-appeals of the objectors were allowed.
The Doctrinal Legacy: An Evidence-Centric Culture
The judgment’s most durable contribution is its operational definition of “efficacy.” The Court anchored the term firmly to therapeutic outcomes concrete, demonstrable improvement in clinical benefit rather than to pharmacokinetic proxies or manufacturing conveniences. This interpretive choice was rooted in the legislative history of Section 3(d), particularly the 2005 amendment introduced precisely to counter the practice of “ever-greening”—the cycle of minor modifications to existing drugs designed to extend patent monopolies without genuine innovation.
In the thirteen years since, this definition has become the default citation for construing pharmaceutical exclusions under Section 3. Controllers at the Patent Office and judges across all levels of the judicial hierarchy now invoke Novartis as the primary guide whenever polymorphs, salts, esters, or new forms of known substances are in issue. Patentees seeking protection for such forms are expected to file robust, clinically anchored evidence of therapeutic superiority not data merely demonstrating better stability or improved bioavailability.
The decision also validated the opposition mechanism as a credible, data-testing filter in high-stakes pharmaceutical matters. The journey through five pre-grant oppositions, IPAB scrutiny, and Supreme Court review demonstrated that these procedural safeguards are not mere formalities but substantive quality- control checkpoints for pharmaceutical patents.
Continuing Influence on Litigation and Interim Relief
The Novartis framework has measurably shaped how pharmaceutical patent disputes are litigated in India today. Courts, particularly the Delhi High Court, now insist on granular claim-to-product mapping and credible prior-art narratives before granting interim injunctive relief. This “evidence first” culture is a direct inheritance of the Supreme Court’s insistence on substantiated patentability.
A striking illustration of this influence is seen in the Semaglutide litigation5, where a credible prima-facie validity challenge grounded in genus disclosures, prior publications, and inventive-step concerns led the court to deny a full injunction and instead craft a calibrated interim order permitting manufacture for export but prohibiting domestic sales. Similarly, in the Roche v. Zydus6 (pertuzumab) proceedings, courts demanded granular technical mapping before any relief was granted an approach that coheres with the evidentiary rigor that Novartis helped entrench. The decision, in short, did not merely refine the meaning of “efficacy”; it ushered in a broader culture of proof for patentability, infringement, and interim relief alike.
A Word on Limitations: The Global Context
It would, however, be intellectually incomplete to present the Novartis ruling as a universal template. Section 3(d) reflects India’s calibrated policy balance between access and innovation and is a jurisdiction-specific provision without a precise analogue in most other patent systems. Many jurisdictions routinely grant patents for polymorphs or salts where inventive step is demonstrated, without imposing a separate “enhanced therapeutic efficacy” filter7. Critics have also argued that India’s high Section 3(d) bar may, at the margins, disincentivize certain incremental improvements such as better patient tolerability or formulation-driven adherence benefits if they cannot be directly tied to clinical efficacy outcomes, even where such improvements offer genuine patient value. In practice, the Novartis ruling’s nuanced distinction between ‘coverage’ and ‘disclosure’ is sometimes misconstrued, with parties asserting that no meaningful demarcation exists.8
Why It Matters: Access, Industry, and Policy
Novartis AG v. Union of India occupies a pivotal place in India’s pharmaceutical patent landscape precisely because it reconciles competing imperatives without fully privileging either . For India’s generic pharmaceutical industry, the decision functions as a strategic lodestar by clearly delineating what fails to satisfy Section 3(d)’s heightened threshold, it enables targeted pre-grant and post-grant oppositions, accelerates legal certainty, and facilitates earlier market entry where follow-on claims are weak—thereby reinforcing India’s role as a global hub for affordable medicines with far-reaching public-health implications.
From the perspective of innovator multinational companies, however, the ruling signals a consciously restrictive approach to incremental pharmaceutical innovation, narrowing the scope for protecting improvements that enhance safety, stability, bioavailability, or patient compliance but fall short of demonstrable therapeutic efficacy. While Novartis provides doctrinal clarity and predictability, it simultaneously shapes R&D incentives, portfolio strategies, and launch sequencing in India, reflecting a deliberate policy choice to prioritise access and competition over broader innovation claims—one that continues to animate debate on whether the balance struck best serves both immediate public-health needs and long-term innovation objectives.
Ultimately it is not a frozen historical precedent, but a continuously operative judicial instrument. It gave concrete content to Section 3(d), established an evidence-centric patentability culture, and rebalanced the patent system’s incentives toward genuine therapeutic advance. Its influence continues to be felt in courts, before Patent Controllers, and in corporate strategy rooms, thirteen years on proof, if any were needed, that a single well-reasoned judgment can reshape an entire jurisprudential field.
Disclaimer – The views expressed in this article are the personal views of the author and are purely informative in nature.
1. Novartis vs Union of India (2013) 6 SCC 1
2. The “mailbox” mechanism was introduced by India pursuant to its TRIPS obligations, whereby pharmaceutical and agro-chemical product patent applications filed between January 1, 1995 and January 1, 2005 were received and preserved without examination, pending the introduction of product patent protection under the Patents (Amendment) Act, 2005. Such applications were examined only after the 2005 amendments came into force.
3. The Intellectual Property Appellate Board (IPAB), which had exercised appellate jurisdiction over patent, trade mark, copyright and allied intellectual property matters, was abolished with effect from 4 April 2021 pursuant to the Tribunals Reforms (Rationalization and Conditions of Service) Ordinance, 2021 (later replaced by the Tribunals Reforms Act, 2021). Consequently all pending proceedings before the IPAB stood transferred to the respective High Courts, and appellate and revocation jurisdiction under the Patents Act, 1970 now vests directly in the High Courts.
4. Zimmermann patent refers to U.S. Patent No. 5,521,184, titled “Pyrimidine derivatives and processes for the preparation thereof”, granted on May 28, 1996 to Jürg Zimmermann (assigned to Novartis). The patent discloses N-phenyl-2-pyrimidine-amine derivatives, including Imatinib in free base form, and constituted the prior art relied upon by Indian authorities and the Supreme Court of India in assessing the patentability of the beta-crystalline form of Imatinib Mesylate under Section 3(d) of the Patents Act, 1970.
5. The Indian semaglutide patent litigation between Novo Nordisk A/S and Dr. Reddy’s Laboratories Ltd. arose from Novo Nordisk’s enforcement of Indian Patent No. 262697, covering the compound semaglutide, a GLP-1 analogue used in the treatment of diabetes and obesity. In interim proceedings, the Delhi High Court declined to restrain Dr. Reddy’s from manufacturing and exporting semaglutide to jurisdictions where Novo Nordisk did not hold patent protection, while recording undertakings restraining domestic sale pending adjudication of validity and infringement. The Court noted that Dr. Reddy’s had raised a prima facie credible challenge to the validity of the suit patent, including on grounds of obviousness and prior claiming, and emphasised that injunctive relief must be assessed in light of the balance of convenience, especially where the patent was close to expiry.
6. In Roche v. Zydus, involving pertuzumab-based claims, the court’s analysis reflects the enduring influence of Novartis in reinforcing the heightened threshold for patentability of incremental pharmaceutical innovations, particularly where claims relate to known substances or their foreseeable derivatives.
7. In contrast to the Indian position under Section 3(d) of the Patents Act, 1970, several major patent jurisdictions do not impose a standalone requirement of “enhanced therapeutic efficacy” for patentability of polymorphs or pharmaceutical salts. Under the European Patent Convention, polymorphs and salts are assessed using the conventional problem–solution approach, and patentability turns on whether the claimed form demonstrates a non-obvious technical effect (such as improved stability, hygroscopicity, or manufacturability), rather than enhanced therapeutic efficacy as such. Similarly, under United States patent law, polymorphs and salts are examined under the ordinary standards of novelty and non-obviousness pursuant to 35 U.S.C. §§ 102 and 103, without a statutory requirement that the claimed form show superior clinical or therapeutic efficacy over known forms.
8. Although the Supreme Court in Novartis AG v. Union of India & Ors. acknowledged that, as a matter of patent theory, claims cannot extend beyond the enabling disclosure, the judgment has at times been selectively relied upon to contend that no meaningful distinction exists between mere coverage of subject matter by a broad genus claim and its disclosure through an enabling teaching. Subsequent decisions of the Delhi High Court have clarified that Novartis does not obliterate the conceptual demarcation between coverage and disclosure but cautions against a patentee asserting infringement of subject matter which it simultaneously claims was never disclosed. The Court has reiterated that whether coverage amounts to disclosure is a fact-specific enquiry, turning on whether the prior art enables a person skilled in the art to arrive at the claimed subject matter without inventive effort.
– Novartis AG v. Union of India & Ors., (2013) 6 SCC 1, ¶¶ 119–120; Novartis AG v. Natco Pharma Ltd., 2023 SCC OnLine Del 106 (clarifying that coverage is not ipso facto disclosure); see also AstraZeneca AB v. Emcure Pharmaceuticals Ltd., Delhi High Court (selection patent context)